GlassScriptPhysician profile
Adam Lesiczka
NPI 1902836919
$2,746.35
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,134 · 2020: $863 · 2021: $750.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $524.94 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $292.38 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.63 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $202.82 | 2019-2021 | |
| Astellas Pharma US INC | $188.85 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $153.46 | 2019-2020 | |
| Pfizer INC. | $142.07 | 2019-2021 | |
| Lilly USA, LLC | $133.26 | 2019-2021 | |
| Amgen INC. | $127.15 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $98.94 | 2019-2021 | |
| Allergan, INC. | $82.83 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $82.00 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $56.85 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $55.45 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $54.71 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $54.44 | 2019-2021 | |
| Abbvie INC. | $52.15 | 2020-2021 | |
| Horizon Therapeutics Plc | $40.27 | 2019 | |
| Genentech USA, INC. | $30.00 | 2019 | |
| Paratek Pharmaceuticals, INC. | $26.36 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.33 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $23.93 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.80 | 2019 | |
| Aprecia Pharmaceuticals, LLC | $14.60 | 2021 | |
| Glaxosmithkline, LLC. | $14.26 | 2020 | |
| Amneal Pharmaceuticals LLC | $13.16 | 2021 | |
| Vertical Pharmaceuticals, LLC | $12.84 | 2019 | |
| Ironwood Pharmaceuticals, INC | $12.84 | 2019 | |
| Scilex Pharmaceuticals INC. | $12.03 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Lesiczka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.